Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN(R) in Combination ... 
MarketWatch (press release)
ZEVALIN (ibritumomab tiuxetan) injection for intravenous use, is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL). ZEVALIN is also indicated for the treatment of patients ...
Spectrum Pharma begins Phase 2 study Of ZEVALIN Injection - quick facts RTT News
Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN in Combination ... Benzinga

all 11 news articles » 

Biovest makes a move on the EU market with BiovaxID 
FierceVaccines
Biovest International's ($BVTI) stock has risen by 15% on two pieces of news about its personalized cancer vaccine for the treatment of follicular non-Hodgkin lymphoma, BiovaxID. The company will seek marketing approval in the EU for the vaccine, ...

and more » 

Biovest to Seek Marketing Approval in the EU for BiovaxID® Personalized ... 
EON: Enhanced Online News (press release)
The EU market has an estimated 23000 patients diagnosed with follicular lymphoma each year which is roughly equal in size to the US market. We believe that with approval, patients and physicians will embrace BiovaxID as being a safe and effective ...

and more » 

Biovest to seek EU marketing nod for lymphoma cancer vaccine, BiovaxID 
pharmabiz.com
The EU market has an estimated 23000 patients diagnosed with follicular lymphoma each year which is roughly equal in size to the US market. We believe that with approval, patients and physicians will embrace BiovaxID as being a safe and effective ...
Biovest Retains Ferghana Partners to Evaluate Strategic Transactions MarketWatch (press release)

all 10 news articles » 

CHOP-RIT, CHOP-R Similar for Follicular Lymphomas 
Clinical Oncology News
Although the trial did not answer how either therapy fits with maintenance rituximab?a strategy that is being increasingly employed in follicular lymphomas (FL)?it is the first major study to compare these alternatives. ?My conclusion is that the ...

 

UPDATE: Cancer Genetics Plans $48.6M IPO 
GenomeWeb
The company added that it is validating its MatBA microarray technology for other lymphoma subtypes, including mantle-cell lymphoma, follicular lymphoma, and diffuse large B cell lymphoma. Cancer Genetics also is developing another microarray ...

and more » 

Identifying Appropriate Patient Groups and Drug Targets in DLBCL 
Cancer Network
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol. 2009;27:3036-43. 5. Levy R, Robertson MJ, ...

and more » 

TG Therapeutics, Inc. Announces Investigational New Drug (IND) for TGTX-1101 ... 
MarketWatch (press release)
Once the optimal dose is determined, up to 77 patients will be enrolled and stratified by subtype of B-cell Lymphoma, including Follicular Lymphoma, Diffuse Large B-Cell Lymphoma and other NHL subtypes for the Phase II component.

and more » 

Plano father helps cure lymphoma one step at a time: 9th annual Lymphomathon ... 
Carrollton Leader
"I was diagnosed with Stage IV non-Hodgkin follicular lymphoma, with the lymphoma having spread to my bone marrow," Runge said. "I saw five doctors and got four different opinions before choosing a doctor at UT-Southwestern. What it came down to was, ...

and more » 

Halozyme Reports First Quarter 2012 Financial Results 
MarketWatch (press release)
Roche reiterated their intent to file the Line Extension Application of subcutaneous MabThera® (rituxumab with rHuPH20) to the EMA this year for the treatment of Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Follicular Lymphoma.

and more »